THE EFFECTIVENESS OF INFLIXIMAB IN CHILDREN WITH IBD, DEPENDING ON THE LEVEL OF CIRCULATING CYTOKINES AND THE CONCENTRATION OF THE DRUG



Cite item

Full Text

Abstract

In this study, we assessed the blood circulating proinflammatory and inflammatory cytokines and obtained the cut-off level for TNF, IL-22, IL-23, IL-27 between groups of children in exacerbation and remission during treatment with infliximab. There was a significant decrease in serum IFN in children in exacerbation compared with the group of children in remission for both UC and CD. It was found that the younger the age of the child, the faster the antibodies to infliximab were formed. The level of TNFin the blood, the residual level of infl iximab, as well as the level of antibodies to infliximab can serve as predictors of non-response and loss of effect from therapy with TNF blockers.

About the authors

T. V. Radygina

National Medical Research Center for Children’s Health

Author for correspondence.
Email: Radygina.TV@nczd.ru

Ph.D. (Medicine), Senior Research Associate, Laboratory of Experimental Immunology and Virology, 

Moscow

Russian Federation

A. S. Illarionov

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

PhD student of the Gastroenterological department with hepatological group,

Moscow

Russian Federation

D. G. Gerasimova

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

intern oftheLaboratory of Experimental Immunology and Virology,

Moscow

Russian Federation

A. O. Anushenko

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

pediatrician of the Gastroenterological department with hepatological group,

Moscow

Russian Federation

Y. A. Komakh

The S. Fyodorov Eye Microsurgery Federal State Institution

Email: fake@neicon.ru

PhD, Head of the Transplantology and Cellular Biology Laboratory,

Moscow

Russian Federation

A. S. Potapov

National Medical Research Center for Children’s Health

Email: fake@neicon.ru
Moscow Russian Federation

S. V. Petrichuk

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

PhD, MD (Biology), Professor, Main Research Associate, Laboratory of Experimental Immunology and Virology,

Moscow

Russian Federation

A. P. Fisenko

National Medical Research Center for Children’s Health

Email: fake@neicon.ru

Head of the National Medical Research Center for Children’s Health,

Moscow

Russian Federation

References

  1. Ungar B., Levy I., Yavne Y., Yavzori M., Picard O., Fudim E., Loebstein R., Chowers Y., Eliakim R., Kopylov U., Ben-Horin S. Optimizing Anti-TNF-α Therapy: Serum Levels ofInfliximab and Adalimumab Are Associated With Mucosal Healing in Patients WithInflammatory Bowel Diseases. Clin Gastroenterol Hepatol 2016;14:550–7.
  2. Hanauer S. B., Wagner C. L., Bala M., Mayer L., Travers S., Diamond R. H., Olson A., Bao W., Rutgeerts P. Incidence and importance of antibody responsesto infliximab after maintenance or episodic treatment in Crohn’s disease. Clin Gastroenterol Hepatol 2004;2:542–53. treatment in Crohn’s disease.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Radygina T.V., Illarionov A.S., Gerasimova D.G., Anushenko A.O., Komakh Y.A., Potapov A.S., Petrichuk S.V., Fisenko A.P.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № 77 - 11525 от 04.01.2002.